ipharmacenter Consulting services

Johnson & Johnson secured European Commission approval for IMAAVY (nipocalimab), a pioneering FcRn-blocking monoclonal antibody used alongside standard therapy for generalized myasthenia gravis (gMG). This breakthrough covers adults and adolescents aged 12+ positive for anti-AChR or anti-MuSK antibodies, representing over 90% of antibody-positive gMG patients. By slashing immunoglobulin G levels, a core trigger of muscle weakness, chewing issues, swallowing problems, and spee

Sun Pharma Launches ILUMYA in India Sun Pharma has unveiled its globally recognized innovative medication, ILUMYA (Tildrakizumab), now available in India for managing moderate-to-severe plaque psoriasis. This advanced biologic therapy has garnered extensive acceptance among dermatologists in the United States and internationally as a reliable and safe option for treating this condition. Also read: Top pharmaceutical companies by revenues in 2025   Long-Term Efficacy of ILUMYA

The U.S. Food and Drug Administration (FDA) has accepted AstraZeneca’s New Drug Application (NDA)  for baxdrostat  under Priority Review , marking a key regulatory milestone for patients with hard‑to‑control or treatment‑resistant hypertension. The application seeks approval for baxdrostat as an add‑on therapy to existing antihypertensive treatments in adult patients whose blood pressure remains inadequately controlled despite standard care. Also read: Top 10 pharmaceutical c

The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly's Jaypirca (pirtobrutinib), making it the first and only non-covalent, reversible Bruton tyrosine kinase (BTK) inhibitor approved to treat adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously received covalent BTK inhibitor therapy. The approval also converts the company's December 2023 accelerated approval into a tradi

BEST SELLING CANCER DRUGS | TOP ONCOLOGY DRUGS | 2025 Best‑Selling Cancer Drugs 2025: Top 10 Brands, Uses and MOA Rank Brand Revenues 1 Keytruda $ 23.3 billion 2 Darzalex $ 10.4 billion 3 Opdivo $ 7.4 billion 4 Tagrisso $ 5.4 billion 5 Imfinzi $ 4.3 billion 6 Verzenio $ 4.1 billion 7 Kisqali $ 3.5 billion 8 Tecentriq $ 3.3 billion 9 Ibrance $ 3.0 billion 10 Perjeta $ 2.9 billion In 2025, global oncology revenues continue to be dominated by immune checkpoint inhibitors and tar

Top pharmaceutical companies by revenues in 2025. The revenues are captured from the official websites of pharmaceutical companies

Bristol Myers Squibb is extending enrollment in its pivotal ADEPT-2 Phase 3 trial of Cobenfy in psychosis associated with Alzheimer’s disease, following a review of site-level data and a recommendation from the study’s independent Data Monitoring Committee (DMC). The company remains blinded to efficacy and safety outcomes from the study.​ Also read: Top pharmaceutical companies by revenues | 2025   Study continuation after data review During a blinded quality review of ADEPT-

Dual Special Needs Plans (D-SNPs) are Medicare Advantage plans designed for individuals eligible for both Medicare and Medicaid, offering coordinated coverage that integrates medical, prescription, and supplemental benefits to address complex needs. These plans cover Medicare Parts A, B, and often D alongside Medicaid services like long-term care and behavioral health support, typically with low or no cost-sharing. UnderstandingD-SNPs for Dual Eligibles D-SNPs target "dual el

Eli Lilly has cut out‑of‑pocket prices for its obesity drug Zepbound in the United States, lowering the monthly cost of single‑dose vials for patients who pay cash through its LillyDirect platform in an effort to broaden access to tirzepatide.​   New Zepbound vial pricing and regular prices Under the updated Zepbound Self‑Pay Journey Program on LillyDirect, patients with a valid prescription can now obtain the starter 2.5 mg vial for about 299 dollars per month, down from rou

Switzerland’s new understanding with the US goes beyond a minor tariff tweak and directly touches the country’s role as a pharma and med‑tech hub. Under a November memorandum of understanding, Washington will cap the country‑specific additional tariff on Swiss goods at 15%, bringing Switzerland into line with the EU and EFTA - while key pharmaceutical products remain largely exempt from the surcharge but under continued scrutiny.​   What the Switzerland–United States deal doe

NICE’s decision to accept higher cost‑per‑QALY ratios is more than a technical parameter change; it reflects a domestic adjustment to a broader bargain the UK has struck with the United States to pay more for branded medicines in return for zero tariffs on British pharmaceutical exports. That combination of trade and health‑policy concessions is likely to shape how other tax‑funded health systems define value, manage finite drug budgets and approach negotiations with global m

The UK government announced on December 1, 2025, an increase in the National Institute for Health and Care Excellence (NICE) thresholds used to evaluate new medicines' cost-effectiveness for the National Health Service (NHS). NICE increased cost effectiveness threshold from £20,000-£30,000/QALY to £25,000-£35,000/QALY This adjustment raises the standard range from £20,000 - £30,000 per quality-adjusted life year (QALY) gained to £25,000 - £35,000 per QALY, aiming to foster in

CMS has introduced the ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) Model, a new 10‑year voluntary payment model in Original Medicare designed to expand technology‑supported care for people living with chronic diseases. The first performance period begins July 1, 2026, with applications due by April 1, 2026; applications submitted after that date will be considered for a January 1, 2027 start.​   What is the ACCESS Model? The ACCESS Model tests an outcom

FDA approved Imfinzi for perioperative use The U.S. FDA approved Imfinzi (durvalumab) as the first and only perioperative immunotherapy for adults with resectable stage II–IVA gastric and gastroesophageal junction (GEJ) cancers, in combination with FLOT chemotherapy before surgery, continued with FLOT plus Imfinzi after surgery, and followed by Imfinzi monotherapy. The decision was granted Priority Review and evaluated under the FDA’s Project Orbis framework, enabling coordin

Dupixent (dupilumab) has been approved in the European Union as the first targeted therapy in more than a decade for chronic spontaneous urticaria (CSU) in patients 12 years and older whose disease remains uncontrolled on standard antihistamines and who are naïve to anti‑IgE therapy. This decision offers a new first‑line biologic option for an estimated 270,000 adolescents and adults in the EU with CSU inadequately controlled by H1 antihistamines.   Also read: Top 10 pharmace

The U.S. Food and Drug Administration has endorsed Kygevvi (doxecitine and doxribtimine) oral powder, marking the inaugural authorized remedy for thymidine kinase 2 deficiency (TK2d) among grown-ups and young patients showing signs by age 12 or earlier.   Developed by UCB, the drug targets a devastating mitochondrial disorder previously limited to symptom management alone. Grasping TK2d Challenges TK2d represents a scarce inherited condition disrupting mitochondrial DNA produ

China’s NMPA has approved Pfizer’s matazisimab (You Ruiting) for routine prophylaxis in hemophilia A or B patients with inhibitors, backed by pivotal BASIS data

The Centers for Medicare & Medicaid Services (CMS) announced a projected net savings of 44%, or $12 billion, on 15 widely used drugs for cancer and other chronic conditions, building on efforts to make prescriptions more affordable for Medicare beneficiaries. Under the Maximum Fair Price (MFP) negotiation policy, established as part of the Biden administration’s Inflation Reduction Act, CMS has negotiated lower prices for high-cost drugs, with these new prices set to take ef

The Centers for Medicare & Medicaid Services (CMS) has proposed new policies for Medicare Advantage (MA) and Medicare Part D plans, aiming to improve quality, boost access, and support innovative benefit designs. The 2027 draft rule details significant changes to the Star Ratings system and invites public comments on how to further modernize Medicare Advantage for both beneficiaries and taxpayers.   Also read: Top 10 pharmaceutical companies by revenues Under these proposed u

Hundreds of adults in England living with a rare and aggressive form of blood cancer could soon access a potentially life-saving therapy, following new guidance from the National Institute for Health and Care Excellence (NICE).   NICE has recommended obecabtagene autoleucel, also known as obe-cel or Aucatzyl, for routine NHS use in patients aged 26 and over with relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL). The decision marks an important step forward for

East Hanover, N.J., [November 24, 2025] - Novartis announced today that the U.S. Food and Drug Administration (FDA) has approved Itvisma (onasemnogene abeparvovec) for the treatment of children two years and older, as well as adolescents and adults living with spinal muscular atrophy (SMA) with a confirmed mutation in the survival motor neuron 1 (SMN1) gene. This approval makes Itvisma the first and only gene replacement therapy available for this broad population of people a

Get the definitive ranking of the top-selling pharmaceutical drugs by global revenue in 2025. See which blockbusters—from Keytruda to the GLP-1 therapies like Ozempic and Mounjaro—are leading the market and driving record sales in Oncology and Immunology.

Germany’s Federal Health Minister Nina Warken has signaled significant reforms to the country’s healthcare system, stressing that structural changes are unavoidable as statutory health insurance (GKV) faces mounting financial pressure

Merck announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa) in combination with Padcev (enfortumab vedotin) for the perioperative treatment of adults with muscle‑invasive bladder cancer (MIBC) who are ineligible for cisplatin‑based chemotherapy. The regimen includes neoadjuvant therapy before surgery followed by adjuvant treatment after cystectomy. These approvals mark the

Novartis has released new financial targets, forecasting annual sales growth of 5–6% at constant currencies from 2025 through 2030. This updated mid-term outlook extends the recent upward revision for 2024–2029, now set at a 6% constant currency compound annual growth rate (CAGR). Also read: Top pharmaceutical companies by revenues | 2025 The company anticipates growth in its oncology business to play a key role in driving revenue. Novartis has lifted the peak sales projectio

Roche recently disclosed promising findings from the phase III lidERA Breast Cancer trial, where their experimental oral drug, giredestrant, showed a significant improvement in invasive disease-free survival compared to standard endocrine therapies. This study involved over 4,100 patients diagnosed with early-stage breast cancer characterized by oestrogen receptor-positive (ER+), HER2-negative tumors. The trial’s interim analysis revealed that giredestrant not only met but su

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved Epkinly (epcoritamab) administered subcutaneously in combination with rituximab and lenalidomide (EPKINLY + R2) for adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least one prior systemic therapy. This newly approved regimen is the first and only bispecific antibody combination therapy available for this patient population. The approval was granted base

Bristol Myers Squibb Bristol Myers Squibb Unveils Promising Sotyktu Results for Psoriatic Arthritis and Lupus at ACR Conference Bristol Myers Squibb has unveiled new data from late-breaking clinical studies highlighting the promise of Sotyktu (deucravacitinib) in treating both psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE). These findings, from the pivotal Phase 3 POETYK PsA-1 trial and integrated Phase 2 PAISLEY-SLE and long-term extension studies. Psoriati

Novo Nordisk, has taken a significant step in expanding its innovative portfolio by announcing the acquisition of Akero Therapeutics, a clinical-stage company specializing in treatments for serious metabolic diseases. This deal, valued at approximately $4.7 billion cash with a potential additional $0.5 billion pending regulatory approval, aims to enhance Novo Nordisk’s pipeline for metabolic dysfunction-associated steatohepatitis (MASH), one of the most rapidly growing obesit

Johnson & Johnson achieved a milestone on October 7, 2025, as the U.S. FDA approved Simponi (golimumab) for pediatric patients aged at least 2 years and weighing at least 15 kg, living with moderately to severely active ulcerative colitis (UC). This regulatory win makes Simponi the first biologic approved for children in this patient group that can be administered on a once-monthly schedule-helping young patients manage a complex disease with far fewer treatment disruptions.

Daiichi Sankyo has made significant strides in oncology research and care, announcing several developments in the first week of October.   The company filed for regulatory approval of Enhertu as a first-line therapy for HER2-positive metastatic breast cancer, combining it with pertuzumab to target aggressive, treatment-resistant tumors.   In the U.S., the FDA accepted a supplemental application for a unique regimen offering Enhertu followed by THP before surgery, aiming to im

On September 30, Novartis announced that the U.S. Food and Drug Administration’s approval of Rhapsido (remibrutinib) for chronic spontaneous urticaria (CSU). This innovative therapy is the first oral, targeted BTK inhibitor designed exclusively for CSU- a condition marked by unpredictable outbreaks of hives and severe itching, adversely affecting millions

AbbVie announced positive topline results from its second Phase 3 UP-AA trial for the alopecia areata treatment, Rinvoq (upadacitinib). The study showed that both the 15 mg and 30 mg doses of the drug met the primary endpoint, leading to significant scalp hair regrowth in a large percentage of patients after 24 weeks. A key finding from the trial was the significant difference in outcomes compared to placebo. At week 24, 45.2% of patients on the 15 mg dose and 55.0% of those

FDA approved Novo Nordisk’s Wegovy for MASH Treatment

The U.S. Food and Drug Administration (FDA) has approved GSK’s biologic therapy, Nucala (mepolizumab), as an add-on maintenance treatment...

Most Anticipated New Drug Launches of 2025 The pharmaceutical industry is set for another groundbreaking year in 2025, with several...

Novartis has announced plans to acquire Anthos Therapeutics, a biopharmaceutical company specializing in cardiovascular treatments, for...

Top selling drugs of 2024 Sl No Brand Q1 Revenues 1 Keytruda $29.5 billion 2 Ozempic $16.7 billion 3 Dupixent $13.4 billion 4 Eliquis $...

AstraZeneca and Daiichi Sankyo have announced that the U.S. Food and Drug Administration (FDA) has approved Enhertu (trastuzumab...

CHMP gave a positive opinion for treating BMS' cell-therapy Breyanzi for relapsed or refractory follicular lymphoma Bristol Myers Squibb...

TOP PHARMACEUTICAL COMPANIES BY REVENUES IN 2024 | BIGGEST PHARMA OF 2024 Sl No Company Q1 Q2 Q3 Total Best selling products 1 JOHNSON AND JOHNSON $21.8 $43.8 $66.1 $88.8 Stelara, Darzalex, Imbruvica 2 ROCHE $15.8 $34.8 $51.9 $66.4 Ocrevus, Perjeta, Tecentriq, Hemlibra, Kadcyla, Alecensa, Mabthera/Rituxan 3 PFIZER $14.9 $28.2 $45.9 $63 Comirnaty, Paxlovid, Prevenar 13, Ibrance, Eliquis 4 MERCK $14.0 $28.4 $43.4 $57 Keytruda, Lagevrio, Januvia, Gardasil/Gardasil9 5 ABBVIE $12.

Roche has announced that its investigational drug, Itovebi (inavolisib), in combination with palbociclib and fulvestrant, has...

Pfizer's Targeted Therapy Shows Promising Results for Metastatic Colorectal Cancer with BRAF V600E Mutation Pfizer has shared positive...

Sanofi announced that Sarclisa (isatuximab) has been approved by the European Union (EU) for use in combination with the standard-of-care...

Novo Nordisk has announced promising results from its STEP UP phase 3b trial, revealing that a 7.2 mg dose of semaglutide administered...

In a strategic move to advance cancer therapeutics, AbbVie and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, have...

Eli Lilly has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Omvoh (mirikizumab) as a treatment for...

Johnson & Johnson has announced a step in bolstering its leadership in neuroscience with the acquisition of Intra-Cellular Therapies, a...

GSK Showcases Strong Growth and Future Innovations at JP Morgan 2025 Healthcare Conference At the 2025 JP Morgan Healthcare Conference,...

New Subcutaneous Formulation of Sarclisa Achieves Key Objectives in IRAKLIA Phase 3 Study for Multiple Myeloma A subcutaneous (SC)...